HFpEF Clinical Trials

AMBER-HFpEF (Assessment of CK-586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF) 

Status: Enrolling  

AMBER-HFpEF is a Phase 2 randomized, placebo-controlled, double-blind, multi-center, dose-finding clinical trial evaluating the effect of treatment with CK-586 in patients with symptomatic HFpEF with left ventricular ejection fraction (LVEF) ≥60%.  

The primary objective is to evaluate the safety and tolerability profile of CK-586 compared to placebo.